Patent ID: 6217858
Filing Date: 2001-04-17
Classification: A61K,A61P,C07K,Y10S

Abstract:
A method for inhibiting the infection of hepatocytes by HBV, comprising administering to a human patient a soluble active agent which inhibits the interaction between human interleukin 6 (hIL6) and hepatocytes, and thereby inhibits the activation of gp130 and the internalization of HBV into the hepatocytes, said soluble active agent selected from the group consisting of glycoprotein 80 (gp80) having receptor sites which interact with hIL6, soluble glycoprotein 130 (gp130) having receptor sites which interact with hIL6, hIL6 derived petide LYS41-ALA56, hIL6 derived peptide GLY77-GLU95, hIL6 derived peptide GLN153-HIS165, a combined .beta.1 and .beta.2 hIL6 mutant (mhIL6.beta.1+.beta.2), mhIL6.beta.1+.beta.2 substituted with phe 171 to leu and ser 177 to arg, a soluble active agent which disrupts the hIL6/hIl6R.alpha. complex with hIL6R.beta., and mixtures of any of the foregoing.